• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.
【24h】

Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.

机译：在严重哮喘中禁用生物制剂的炎症途径并导致临床结果。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Patients with severe asthma have a significant unmet need with persistent symptoms and/or frequent exacerbations despite high intensity treatment. These severe unrelenting symptoms have a huge impact on heathcare resources due to frequent hospital admissions and requirement for intensive and expensive medications. There is a compelling need for more effective and safer therapies to help severe asthma sufferers to achieve adequate control of their disease. AREAS COVERED: Expanding knowledge of innate and adaptive immune responses has led to development of new biologic approaches for severe asthma. Here, the authors will review the existing efficacy and safety data from clinical trials of some of the new biologic therapies that are in development for severe asthma. Their specific role in distinctively targeted subpopulations of severe asthmatics will be also discussed. EXPERT OPINION: Defining and phenotyping severe asthma patients will become increasingly important as some patients who were previously classified as having severe asthma may become well-controlled with a targeted phenotype-specific treatment. However, pharmacoeconomic concerns should also be taken into account given the elevated acquisition costs of recombinant human monoclonals and of the diagnostic screening procedures for the identification of potential responders.
机译：引言：尽管进行了高强度治疗，重度哮喘患者仍存在持续的症状和/或频繁发作的严重未满足需求。由于频繁入院以及对密集和昂贵药物的需求，这些严重的无情症状对健康护理资源产生了巨大影响。迫切需要更有效，更安全的疗法来帮助严重的哮喘患者实现对疾病的充分控制。覆盖的领域：对先天性和适应性免疫反应的了解不断扩展，导致了针对严重哮喘的新的生物学方法的开发。在这里，作者将回顾一些针对严重哮喘的新生物疗法的临床试验中现有的疗效和安全性数据。还讨论了它们在重度哮喘患者的不同靶向亚群中的特定作用。专家意见：定义和表型重度哮喘患者将变得越来越重要，因为某些先前被分类为重度哮喘的患者可能会通过靶向表型特异性治疗得到良好控制。但是，考虑到重组人单克隆抗体的购置成本增加以及用于鉴定潜在应答者的诊断筛选程序的增加，也应考虑药物经济学的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号